KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biomarin Pharmaceutical (BMRN) Gains from Investment Securities (2016 - 2025)

Historic Gains from Investment Securities for Biomarin Pharmaceutical (BMRN) over the last 17 years, with Q3 2025 value amounting to $2.2 million.

  • Biomarin Pharmaceutical's Gains from Investment Securities fell 6319.35% to $2.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $58.2 million, marking a year-over-year decrease of 2402.61%. This contributed to the annual value of $77.6 million for FY2024, which is 162.61% up from last year.
  • As of Q3 2025, Biomarin Pharmaceutical's Gains from Investment Securities stood at $2.2 million, which was down 6319.35% from $12.3 million recorded in Q2 2025.
  • Biomarin Pharmaceutical's 5-year Gains from Investment Securities high stood at $108.0 million for Q1 2022, and its period low was -$53.7 million during Q4 2022.
  • Over the past 5 years, Biomarin Pharmaceutical's median Gains from Investment Securities value was $9.6 million (recorded in 2021), while the average stood at $18.1 million.
  • Examining YoY changes over the last 5 years, Biomarin Pharmaceutical's Gains from Investment Securities showed a top increase of 27117.23% in 2022 and a maximum decrease of 400101.67% in 2022.
  • Over the past 5 years, Biomarin Pharmaceutical's Gains from Investment Securities (Quarter) stood at $1.4 million in 2021, then tumbled by 4001.02% to -$53.7 million in 2022, then skyrocketed by 107.3% to $3.9 million in 2023, then rose by 25.23% to $4.9 million in 2024, then crashed by 55.67% to $2.2 million in 2025.
  • Its last three reported values are $2.2 million in Q3 2025, $12.3 million for Q2 2025, and $38.8 million during Q1 2025.